HBV垂直传播形式及阻断策略

赵斐; 刘菲; 王中峰; 李海军; 徐红梅

doi:10.3969/j.issn.1001-5256.2019.11.037

HBV垂直传播形式及阻断策略

DOI: 10.3969/j.issn.1001-5256.2019.11.037

1. 吉林大学第一医院产科
2. 吉林大学第一医院肝胆胰内科
3. 吉林大学第一医院转化医学研究院

基金项目:

吉林省科技厅自然科学基金(20180101135JC)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 881
- HTML全文浏览量: 9
- PDF下载量: 321
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-08
- 出版日期: 2019-11-20

Vertical transmission of hepatitis B virus: Modes and blocking strategies

Department of Obstetrics,The First Hospital of Jilin University

Research funding:

摘要

摘要: 在我国,母婴垂直传播是慢性乙型肝炎最主要的传播方式。受孕母体如果处于高病毒载量期,母婴垂直传播阻断失败的几率为10%左右,因此孕期正确管理HBV显得尤为重要。此外,妊娠期对病毒的处理不仅要考虑垂直传播的风险,而且要考虑孕妇的健康和胎儿的安全,每一种治疗或预防选择都需要认真评估。制订合理的抗病毒方法、药物选择、停药时间等能够合理降低母婴传播几率。总结了目前慢性乙型肝炎母婴垂直传播形式及阻断措施,为提高HBV的垂直传播阻断率提供参考。
- 乙型肝炎病毒 /
- 传染性疾病传播,垂直 /
- 抗病毒药
Abstract: Mother-to-child vertical transmission is the main mode of transmission of chronic hepatitis B in China. The probability of failure in blocking vertical transmission is about 10% in pregnant mothers with a high viral load,and therefore,correct management of hepatitis B virus( HBV) is of great importance during pregnancy. In addition,viral treatment during pregnancy should take into account the risk of vertical transmission,the health of pregnant women,and the safety of fetus,and each treatment method or prevention option needs to be carefully evaluated. Reasonable antiviral methods,drug selection,and drug withdrawal time can reduce the probability of mother-to-child transmission. This article summarizes the modes of mother-to-child vertical transmission of chronic hepatitis B and related blocking strategies,so as to provide a reference for improving the blocking rate of vertical transmission of HBV.
- hepatitis B virus /
- infectious disease transmission,vertical /
- antiviral agents

HTML全文

参考文献(56)

[1] JIA Y,LI L,LI XG,et al. Analysis of antiviral regimen in outpatients with chronic hepatitis B[J]. Chin J Clin Pharmacol,2017,33(22):2308-2310.(in Chinese)贾莹，李璐，李晓光，等．慢性乙型病毒性肝炎患者抗病毒药物使用情况分析[J]．中国临床药理学杂志，2017,33(22):2308-2310.

[2] LIU YL,KUANG JQ,ZHANG R,et al. Analysis about clinical data of intrauterine infection of hepatitis B virus[J]. Chin J Obstetr Gynecol,2002,37(8):465-468.(in Chinese)刘颖琳，邝健全，张睿，等．胎儿感染乙型肝炎病毒的临床研究[J]．中华妇产科杂志，2002,37(8):465-468.

[3] SARIN SK,KUMAR M,SHRIVASTAVA S,et al. Influence of chronic HBV infection on pregnancy:A human model of maternofetal virus host interactions[J]. Gastroenterology,2011,141(4):1522-1525.

[4] BAI H,ZHANG L,MA L,et al. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism[J]. World J Gastroenterol,2007,13(26):3625-3630.

[5] LIN HH,LEE TY,CHEN DS,et al. Transplacental leakage of HBe Ag-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus[J]. J Pediatr,1987,111(6 Pt 1):877-881.

[6] YI W,PAN CQ,HAO JZ,et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers[J]. J Hepatol,2014,60(3):523-529.

[7] BAI GQ,LI SH,YUE YF,et al. The study on role of peripheral blood mononuclear cell in HBV intrauterine infection[J]. Arch Gynecol Obstet,2011,283(2):317-321.

[8] WONG VC,LEE AK,IP HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant[J]. Br J Obstet Gynaecol,1980,87(11):958-965.

[9] PAO CC,YAO DS,LIN MY,et al. Hepatitis B virus DNA in cervicovaginal cells[J]. Arch Pathol Lab Med,1991,115(6):607-609.

[10] BEASLEY RP,STEVENS CE,SHIAO IS,et al. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B[J]. Lancet,1975,2(7938):740-741.

[11] LI XM,SHI MF,YANG YB,et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection[J]. World J Gastroenterol,2004,10(21):3215-3217.

[12] HAN GR,CAO MK,ZHAO W,et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol,2011,55(6):1215-1221.

[13] HAN L,ZHANG HW,XIE JX,et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J]. World J Gastroenterol,2011,17(38):4321-4333.

[14] CHEN HL,LEE CN,CHANG CH,et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J]. Hepatology,2015,62(2):375-386.

[15] ZHANG H,PAN CQ,PANG Q,et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology,2014,60(2):468-476.

[16] HAN GR,JIANG HX,YUE X,et al. Efficacy and safety of telbivudine treatment:An open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Viral Hepat,2015,22(9):754-762.

[17] PIRATVISUTH T,HAN GR,POL S,et al. Comprehensive review of telbivudine in pregnant women with chronic hepatitis B[J]. World J Gastroenterol,2016,8(9):452-460.

[18] BRIDGES EG,SELDEN JR,LUO S. Nonclinical safety profile of telbivudine,a novel potent antiviral agent for treatment of hepatitis B[J]. Antimicrob Agents Chemother,2008,52(7):2521-2528.

[19] LIU M,CAI H,YI W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy[J]. J Viral Hepat,2013,20(Suppl 1):65-70.

[20] ter BORG MJ,LEEMANS WF,de MAN RA,et al. Exacerbation of chronic hepatitis B infection after delivery[J]. J Viral Hepat,2008,15(1):37-41.

[21] APASL consensus group for the treatment of chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B:A 2012 update[J]. J Clin Hepatol,2012,28(8):Ⅰ-ⅩⅩⅠ．(in Chinese)亚太肝病学会慢性乙型肝炎治疗共识工作组．亚太地区慢性乙型肝炎治疗共识(2012最新版)[J]．临床肝胆病杂志，2012,28(8):Ⅰ-ⅩⅩⅠ．

[22] ZHU Q,YU G,YU H,et al. A randomized control trial on interruption of HBV transmission in uterus[J]. Chin Med J(Engl),2003,116(5):685-687.

[23] YUE Y,YANG X,ZHANG S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin:Efficacy and mechanism[J]. Chin Med J(Engl),1999,112(1):37-39.

[24] YUAN J,LIN J,XU A,et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective:A single-centre randomized study[J]. J Viral Hepat,2006,13(9):597-604.

[25] SCHILLING R,IJAZ S,DAVIDOFF M,et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions[J]. J Virol,2003,77(16):8882-8892.

[26] LIANG X,BI S,YANG W,et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine,2009,27(47):6550-6557.

[27] LIANG X,BI S,YANG W,et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. J Infect Dis,2009,200(1):39-47.

[28] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J]. J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ．(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2010年版)[J]．临床肝胆病杂志，2011,27(1):Ⅰ-ⅩⅥ．

[29] Obstetrics Section,Society of Obstetrics and Gynecology,Chinese Medical Association. Clinical guidelines for prevention of mother-to-child transmission of hepatitis B virus(1st Edition)[J]. Chin J Obstetr Gynecol,2013,48(2):151-154.(in Chinese)中华医学会妇产科学分会产科学组．乙型肝炎病毒母婴传播预防临床指南(第1版)[J]．中华妇产科杂志，2013,48(2):151-154.

[30] CHEN HL,LIN LH,HU FC,et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J]. Gastroenterology,2012,142(4):773-781.

[31] ZOU H,CHEN Y,DUAN Z,et al. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers[J]. PLo S One,2011,6(10):e26748.

[32] KUBO A,SHLAGER L,MARKS AR,et al. Prevention of vertical transmission of hepatitis B:An observational study[J].Ann Intern Med,2014,160(12):828-835.

[33] LIN X,GUO Y,ZHOU A,et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population:A hospital-based study and a meta-analysis[J]. Pediatr Infect Dis J,2014,33(9):897-903.

[34] WANG JS,CHEN H,ZHU QR. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers[J]. World J Gastroenterol,2005,11(23):3582-3585.

[35] KANG W,DING Z,SHEN L,et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province,China[J]. Vaccine,2014,32(27):3362-3366.

[36] FAN XH,HU YL,ZHU HL. Study on YMDD mutation during Lamivudine therapy of chronic hepatitis B[J]. J Clin Hepatol,2009,25(3):192-194.(in Chinese)樊晓红，胡玉琳，朱红玲．拉米夫定治疗慢性乙型肝炎发生YMDD变异的研究[J]．临床肝胆病杂志，2009,25(3):192-194.

[37] LIU JH,JIANG PR. Prevention of vertical transmission of hepatitis B virus from mother to child in perinatal period[J/CD].Chin J Obstet Emerg:Electronic Edition,2017,6(3):175-179.(in Chinese)刘晶华，蒋佩茹．围产期乙型肝炎病毒母婴垂直传播的防治[J/CD]．中华产科急救电子杂志，2017,6(3):175-179.

[38] CADRANEL S,ZEGHLACHE S,FERNANDEZ S,et al. Vaccination of newborns of HBsAg-positive carrier mothers with a recombinant DNA hepatitis B vaccine[J]. Postgrad Med J,1987,63(Suppl 2):159-160.

[39] HALLIDAY ML,KANG LY,RANKIN JG,et al. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai,China[J]. Int J Epidemiol,1992,21(3):564-573.

[40] Centers for Disease Control and Prevention(CDC). Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data—United States[J]. MMWR Morb Mortal Wkly Rep,2011,60(13):410-413.

[41] MAST EE,MARGOLIS HS,FIORE AE,et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:Recommendations of the Advisory Committee on Immunization Practices(ACIP)part 1:Immunization of infants,children,and adolescents[J]. MMWR Recomm Rep,2005,54(RR-16):1-31.

[42] WHO Publication. Hepatitis B vaccines:WHO position paper-recommendations[J]. Vaccine,2010,28(3):589-590.

[43] ZOU H,CHEN Y,DUAN Z,et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBs Ag-positive mothers[J]. J Viral Hepat,2012,19(2):e18-e25.

[44] WEN WH,CHANG MH,ZHAO LL,et al. Mother-to-infant transmission of hepatitis B virus infection:Significance of maternal viral load and strategies for intervention[J]. J Hepatol,2013,59(1):24-30.

[45] DANIELSSON N,FAKAKOVIKAETAU T,SZEGEDI E. Improved immunization practices reduce childhood hepatitis B infection in Tonga[J]. Vaccine,2009,27(33):4462-4467.

[46] BOOT HJ,HAHNE S,CREMER J,et al. Persistent and transient hepatitis B virus(HBV)infections in children born to HBV-infected mothers despite active and passive vaccination[J]. J Viral Hepat,2010,17(12):872-878.

[47] LUONGO M,CRITELLI R,GROTTOLA A,et al. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject:Sequence analysis and therapeutic strategy[J]. J Clin Virol,2015,62:89-91.

[48] CHONG-JIN O,WEI NING C,SHIUAN K,et al. Identification of hepatitis B surface antigen variants with alterations outside the“a”determinant in immunized Singapore infants[J]. J Infect Dis,1999,179(1):259-263.

[49] ADKINS B,LECLERC C,MARSHALL-CLARKE S. Neonatal adaptive immunity comes of age[J]. Nat Rev Immunol,2004,4(7):553-564.

[50] ELAHI S,ERTELT JM,KINDER JM,et al. Immunosuppressive CD71 erythroid cells compromise neonatal host defence against infection[J]. Nature,2013,504(7478):158-162.

[51] BEASLEY RP,HWANG LY,LEE GC,et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine[J]. Lancet,1983,2(8359):1099-1102.

[52] MILICH DR,JONES JE,HUGHES JL,et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?[J]. Proc Natl Acad Sci U S A,1990,87(17):6599-6603.

[53] PUBLICOVER J,GAGGAR A,NISHIMURA S,et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B[J]. J Clin Invest,2013,123(9):3728-3739.

[54] KENNEDY PTF,SANDALOVA E,JO J,et al. Preserved Tcell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology,2012,143(3):637-645.

[55] GIBBONS D,FLEMING P,VIRASAMI A,et al. Interleukin-8(CXCL8)production is a signatory T cell effector function of human newborn infants[J]. Nat Med,2014,20(10):1206-1210.

[56] HONG M,SANDALOVA E,LOW D,et al. Trained immunity in newborn infants of HBV-infected mothers[J]. Nat Commun,2015,6:6588.

施引文献

资源附件(0)

访问统计